CancerTYPE ID^® Offers Convenient Billing and Medicare Coverage

CancerTYPE ID^® is now one of the few molecular oncology tests covered by Medicare policy.

bioTheranostics is pleased to announce that Medicare, through its Medicare Administrative Contractor Palmetto GBA, has issued a coverage determination authorizing reimbursement for CancerTYPE ID^®. It is a covered benefit for Medicare Part B patients.

Evidence Base

This coverage decision is based on a review of evidence supporting the analytical validity, clinical validity, and clinical utility of CancerTYPE ID^®.

Local Coverage Determination

• CPT code 84999
• Covered by Medicare at 100%
• No co-payment

Effort-free Billing and Reimbursement Services

bioTheranostics accepts formal assignment of benefits whenever possible and submits insurance claims on behalf of insured patients within the United States.

• Reimbursement Services: We work directly with third-party payers to ensure maximum benefit and coverage for patients, including filing for appeals as necessary.
• Patient Assistance Program (PAP): We strive to ensure that all patients have access to our testing services, regardless of financial circumstances.
  • Certain financial information will be required to determine individual levels of support. bioTheranostics can confirm the level of coverage available from specific insurance providers on an as-needed basis.

CancerTYPE ID Indications for Use and Limitations
CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database.